Recent studies show that endocannabinoids play a significant role when it comes the regulating of the cardiovascular function in varied conditions.
According to the research conducted by the Neuro-Endoceuticals team, USA, they posit that ECS are endogenous lipid mediators that have a broad range of biological effects that are the same to those of the hemp extract plant.
In this case, Mike Membrino, President of Neuro-Endoceuticals asserts that ECSs are involved in various psychological functions, which include the regulation of appetite by the central mechanism and its impacts of obesity (Cunha, Pedro et., 2011).
On the other hand, in vitro, CB1 acts between the cardiovascular process, including vasodilation that exists in the afferent arterioles of the kidney by the endothelial release of nitric oxide (Cunha, Pedro et., 2011). Additionally, another impact of the ECS is the interest of CB1 receptors that have a high correlation between the concentrations of various cannabinoid agonist that tend to generate hypotensive and bradycardic responses in the brain. In effect, the hypotensive effect of cannabinoid can lead to the acute effect of blood pressure because of the alterations in either peripheral vascular resistance, cardiac output, or both (Cunha, Pedro et., 2011). Finally, the function of cannabinoids in activating vascular and cardiac CB1 receptors has shown the link to numerous forms of circulatory shock and advanced liver cirrhosis. In this case, depending on a particular condition, ECS has varied effects.References
Pacher P, & Steffens, S. (2009). The emerging role of the endocannabinoid system in cardiovascular disease. Seminars in Immunopathology, 31(1), 63–77. http://doi.org/10.1007/s00281-009-0145-8
Cunha, P., Romão, A. M., Mascarenhas-Melo, F., Teixeira, H. M., & Reis, F. (2011). Endocannabinoid system in cardiovascular disorders – new pharmacotherapeutic opportunities. Journal of Pharmacy and Bioallied Sciences, 3(3), 350–360. http://doi.org/10.4103/0975-7406.84435